tag preclinical-research 
Pharmaceutical Technology
DECEMBER 5, 2022
In 2022, a surge in the pipeline has led to cannabinoid receptors becoming the most popular target in preclinical development. Figure 1 shows the targets in preclinical trials for central nervous system diseases, as sourced from GlobalData’s Drugs Database. Cannabinoid-based drugs are derived from compounds found in the cannabis plant.
Rethinking Clinical Trials
JULY 22, 2022
Associate Vice President, Research Partnerships. ACTIV was stood up in about a month, launching on April 17, 2020, to develop a coordinated research response to speed COVID-19 treatment and vaccine options. There were four ACTIV fast-track focus areas: vaccines, preclinical, clinical trial capacity, and therapeutics – clinical.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 29, 2022
Research and drug development for rare diseases has shifted from “niche” to conventional, aided by multiple drivers of growth in the field and favorable legislation. Others judge its success based on the fact that 95% of rare diseases still have no available therapies and patient needs remain unmet.
Drug Discovery World
OCTOBER 31, 2023
The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) have all approved the clinical trial application that was submitted by The University of Manchester in August 2022.
Drug Discovery World
JUNE 14, 2023
At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. But it also makes the research a little bit more complicated.
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. —- End —-.
pharmaphorum
DECEMBER 23, 2022
price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Professional reception of the findings.
Expert insights. Personalized for you.
245 
Let's personalize your content